drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00222 | DB00582 | 245 | 1,622 | [
"DDInter825",
"DDInter1946"
] | Glimepiride | Voriconazole | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Major | 2 | [
[
[
245,
25,
1622
]
],
[
[
245,
6,
6017
],
[
6017,
45,
1622
]
],
[
[
245,
21,
28852
],
[
28852,
60,
1622
]
],
[
[
245,
24,
752
],
[
752,
... | [
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
]
],
[
[
"Glimepiride",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Vor... | Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Voriconazole (Compound)
Glimepiride (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Voriconazole (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine... |
DB00277 | DB11932 | 1,031 | 327 | [
"DDInter1791",
"DDInter3"
] | Theophylline | Abametapir (topical) | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
1031,
24,
327
]
],
[
[
1031,
24,
868
],
[
868,
24,
327
]
],
[
[
1031,
63,
1684
],
[
1684,
24,
327
]
],
[
[
1031,
24,
1619
],
[
1619,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Theo... |
DB00705 | DB12500 | 441 | 283 | [
"DDInter496",
"DDInter714"
] | Delavirdine | Fedratinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
441,
25,
283
]
],
[
[
441,
23,
466
],
[
466,
62,
283
]
],
[
[
441,
25,
351
],
[
351,
23,
283
]
],
[
[
441,
63,
1419
],
[
1419,
2... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Delavirdine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Delavirdine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may caus... |
DB00467 | DB06203 | 1,467 | 1,002 | [
"DDInter644",
"DDInter51"
] | Enoxacin | Alogliptin | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1467,
24,
1002
]
],
[
[
1467,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1467,
64,
176
],
[
176,
24,
1002
]
],
[
[
1467,
40,
1299
],
[
1299... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Enoxacin may lead to a major life threatening interaction when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exac... |
DB00987 | DB08826 | 1,224 | 1,292 | [
"DDInter460",
"DDInter489"
] | Cytarabine | Deferiprone | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
1224,
25,
1292
]
],
[
[
1224,
18,
2215
],
[
2215,
57,
1292
]
],
[
[
1224,
63,
482
],
[
482,
25,
1292
]
],
[
[
1224,
64,
1101
],
[
1101... | [
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Cytarabine",
"{u} (Compound) downregulates {v} (Gene)",
"HSPA8"
],
[
"HSPA8",
"{u} (Gene) is downregulated by {v} (Compound)",... | Cytarabine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Deferiprone (Compound)
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Cytarabine may le... |
DB00816 | DB00960 | 1,674 | 887 | [
"DDInter1346",
"DDInter1471"
] | Orciprenaline | Pindolol | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Major | 2 | [
[
[
1674,
25,
887
]
],
[
[
1674,
63,
726
],
[
726,
1,
887
]
],
[
[
1674,
24,
819
],
[
819,
40,
887
]
],
[
[
1674,
35,
1148
],
[
1148,
... | [
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betaxolol"
],
[
"Betaxol... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Betaxolol and Betaxolol (Compound) resembles Pindolol (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
... |
DB00358 | DB00906 | 1,010 | 1,567 | [
"DDInter1140",
"DDInter1801"
] | Mefloquine | Tiagabine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Moderate | 1 | [
[
[
1010,
24,
1567
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
1567
]
],
[
[
1010,
21,
28814
],
[
28814,
60,
1567
]
],
[
[
1010,
24,
283
],
[
28... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tiagabine (Compound)
Mefloquine (Compound) causes Affect lability (Side Effect) and Affect lability (Side Effect) is caused by Tiagabine (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Fedratini... |
DB00876 | DB01156 | 1,414 | 593 | [
"DDInter658",
"DDInter252"
] | Eprosartan | Bupropion | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
1414,
24,
593
]
],
[
[
1414,
6,
6017
],
[
6017,
45,
593
]
],
[
[
1414,
7,
12648
],
[
12648,
46,
593
]
],
[
[
1414,
21,
28757
],
[
2875... | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Eprosartan",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Eprosartan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bupropion (Compound)
Eprosartan (Compound) upregulates GPER1 (Gene) and GPER1 (Gene) is upregulated by Bupropion (Compound)
Eprosartan (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Eprosarta... |
DB00047 | DB01359 | 176 | 729 | [
"DDInter932",
"DDInter1417"
] | Insulin glargine | Penbutolol | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
176,
24,
729
]
],
[
[
176,
24,
461
],
[
461,
1,
729
]
],
[
[
176,
24,
699
],
[
699,
40,
729
]
],
[
[
176,
24,
542
],
[
542,
23,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
... |
DB01132 | DB04946 | 1,130 | 924 | [
"DDInter1472",
"DDInter907"
] | Pioglitazone | Iloperidone | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
1130,
24,
924
]
],
[
[
1130,
63,
1664
],
[
1664,
1,
924
]
],
[
[
1130,
24,
519
],
[
519,
40,
924
]
],
[
[
1130,
6,
12523
],
[
12523,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone... |
DB01017 | DB04398 | 1,669 | 193 | [
"DDInter1224",
"DDInter1015"
] | Minocycline | Lactic acid | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste. It is produced by fermentation of a sugar source, such as ... | Moderate | 1 | [
[
[
1669,
24,
193
]
],
[
[
1669,
63,
663
],
[
663,
23,
193
]
],
[
[
1669,
40,
1620
],
[
1620,
24,
193
]
],
[
[
1669,
1,
1545
],
[
1545,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactic acid"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Lactic acid
Minocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction t... |
DB00877 | DB08822 | 629 | 911 | [
"DDInter1678",
"DDInter156"
] | Sirolimus | Azilsartan medoxomil | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
629,
24,
911
]
],
[
[
629,
63,
217
],
[
217,
1,
911
]
],
[
[
629,
21,
28989
],
[
28989,
60,
911
]
],
[
[
629,
24,
1450
],
[
1450,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
],
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Sirolimus (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Azilsartan medoxomil (Compound)
Sirolimus may ca... |
DB00352 | DB00982 | 482 | 1,517 | [
"DDInter1814",
"DDInter991"
] | Tioguanine | Isotretinoin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Moderate | 1 | [
[
[
482,
24,
1517
]
],
[
[
482,
24,
640
],
[
640,
25,
1517
]
],
[
[
482,
21,
28784
],
[
28784,
60,
1517
]
],
[
[
482,
63,
362
],
[
362,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Isotretinoin
Tioguanine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Isotretinoin (Compo... |
DB00472 | DB00738 | 758 | 485 | [
"DDInter758",
"DDInter1420"
] | Fluoxetine | Pentamidine | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
758,
24,
485
]
],
[
[
758,
6,
12523
],
[
12523,
45,
485
]
],
[
[
758,
18,
9275
],
[
9275,
46,
485
]
],
[
[
758,
7,
12657
],
[
12657,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Fluoxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Fluoxetine (Compound) downregulates RNF167 (Gene) and RNF167 (Gene) is upregulated by Pentamidine (Compound)
Fluoxetine (Compound) upregulates NSDHL (Gene) and NSDHL (Gene) is downregulated by Pentamidine (Compound)
Fluoxetin... |
DB00476 | DB01105 | 109 | 222 | [
"DDInter608",
"DDInter1665"
] | Duloxetine | Sibutramine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
109,
25,
222
]
],
[
[
109,
6,
6112
],
[
6112,
45,
222
]
],
[
[
109,
54,
19202
],
[
19202,
15,
222
]
],
[
[
109,
21,
29215
],
[
29215,
... | [
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sibutr... | Duloxetine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Sibutramine (Compound)
Duloxetine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class) and Norepinephrine Uptake Inhibitors (Pharmacologic Class) includes Sibutramine (Compound)
Duloxetine (Compound) causes Ecchymosis (S... |
DB00364 | DB00489 | 417 | 17 | [
"DDInter1717",
"DDInter1704"
] | Sucralfate | Sotalol | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Minor | 0 | [
[
[
417,
23,
17
]
],
[
[
417,
62,
88
],
[
88,
40,
17
]
],
[
[
417,
21,
28882
],
[
28882,
60,
17
]
],
[
[
417,
24,
115
],
[
115,
62,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoprolol"
],
[
"Me... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Sucralfate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sotalol (Compound)
Sucralfate may cau... |
DB00106 | DB09078 | 618 | 1,228 | [
"DDInter4",
"DDInter1036"
] | Abarelix | Lenvatinib | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
618,
24,
1228
]
],
[
[
618,
23,
112
],
[
112,
23,
1228
]
],
[
[
618,
24,
1100
],
[
1100,
24,
1228
]
],
[
[
618,
24,
938
],
[
938,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafa... |
DB00619 | DB11979 | 1,419 | 1,320 | [
"DDInter909",
"DDInter625"
] | Imatinib | Elagolix | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1419,
24,
1320
]
],
[
[
1419,
63,
608
],
[
608,
23,
1320
]
],
[
[
1419,
23,
271
],
[
271,
23,
1320
]
],
[
[
1419,
24,
1612
],
[
1612,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Li... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Elagolix
Imatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cau... |
DB00852 | DB11827 | 1,445 | 433 | [
"DDInter1545",
"DDInter669"
] | Pseudoephedrine | Ertugliflozin | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1445,
24,
433
]
],
[
[
1445,
63,
1121
],
[
1121,
24,
433
]
],
[
[
1445,
24,
959
],
[
959,
24,
433
]
],
[
[
1445,
74,
1466
],
[
1466,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Glipizid... |
DB06595 | DB14444 | 1,491 | 151 | [
"DDInter1214",
"DDInter924"
] | Midostaurin | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1491,
24,
151
]
],
[
[
1491,
63,
66
],
[
66,
24,
151
]
],
[
[
1491,
24,
1619
],
[
1619,
24,
151
]
],
[
[
1491,
25,
375
],
[
375,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Midostaurin may cause a moderate int... |
DB01101 | DB01149 | 60 | 851 | [
"DDInter285",
"DDInter1274"
] | Capecitabine | Nefazodone | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
60,
24,
851
]
],
[
[
60,
21,
29556
],
[
29556,
60,
851
]
],
[
[
60,
24,
384
],
[
384,
63,
851
]
],
[
[
60,
64,
770
],
[
770,
24,... | [
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Capecitabine",
"{u} (Compound) causes {v} (Side Effect)",
"Laryngitis"
],
[
"Laryngitis",
"{u} (Side Effect) i... | Capecitabine (Compound) causes Laryngitis (Side Effect) and Laryngitis (Side Effect) is caused by Nefazodone (Compound)
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with N... |
DB00159 | DB01050 | 940 | 848 | [
"DDInter903",
"DDInter900"
] | Icosapent | Ibuprofen | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
940,
24,
848
]
],
[
[
940,
6,
7720
],
[
7720,
45,
848
]
],
[
[
940,
21,
28898
],
[
28898,
60,
848
]
],
[
[
940,
63,
20
],
[
20,
... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Icosapent",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
... | Icosapent (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Ibuprofen (Compound)
Icosapent (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Ibuprofen (Compound)
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Ten... |
DB01233 | DB09268 | 1,311 | 1,662 | [
"DDInter1197",
"DDInter1464"
] | Metoclopramide | Picosulfuric acid | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1311,
24,
1662
]
],
[
[
1311,
62,
1252
],
[
1252,
23,
1662
]
],
[
[
1311,
63,
1164
],
[
1164,
24,
1662
]
],
[
[
1311,
25,
776
],
[
776... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Metoclopramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
]... | Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and... |
DB00013 | DB01381 | 1,255 | 958 | [
"DDInter1905",
"DDInter819"
] | Urokinase | Ginkgo biloba | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Moderate | 1 | [
[
[
1255,
24,
958
]
],
[
[
1255,
24,
1347
],
[
1347,
24,
958
]
],
[
[
1255,
25,
126
],
[
126,
24,
958
]
],
[
[
1255,
25,
792
],
[
792,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Urokinase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a... |
DB00945 | DB08938 | 1,479 | 1,384 | [
"DDInter20",
"DDInter1112"
] | Acetylsalicylic acid | Magaldrate | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1479,
24,
1384
]
],
[
[
1479,
63,
167
],
[
167,
23,
1384
]
],
[
[
1479,
23,
699
],
[
699,
23,
1384
]
],
[
[
1479,
62,
461
],
[
461,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroco... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken wi... |
DB00065 | DB00762 | 581 | 613 | [
"DDInter923",
"DDInter973"
] | Infliximab | Irinotecan | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Major | 2 | [
[
[
581,
25,
613
]
],
[
[
581,
25,
869
],
[
869,
63,
613
]
],
[
[
581,
24,
599
],
[
599,
24,
613
]
],
[
[
581,
25,
1555
],
[
1555,
2... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Irinotecan"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may... | Infliximab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause ... |
DB00526 | DB09083 | 1,555 | 880 | [
"DDInter1355",
"DDInter996"
] | Oxaliplatin | Ivabradine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1555,
25,
880
]
],
[
[
1555,
24,
480
],
[
480,
24,
880
]
],
[
[
1555,
63,
597
],
[
597,
24,
880
]
],
[
[
1555,
25,
770
],
[
770,
... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoter... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and... |
DB00662 | DB04946 | 717 | 924 | [
"DDInter1873",
"DDInter907"
] | Trimethobenzamide | Iloperidone | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
717,
24,
924
]
],
[
[
717,
24,
1664
],
[
1664,
1,
924
]
],
[
[
717,
1,
1425
],
[
1425,
25,
924
]
],
[
[
717,
24,
519
],
[
519,
4... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Trimethobenzamide (Compound) resembles Cisapride (Compound) and Cisapride may lead to a major life threatening interaction when taken with Iloperidone... |
DB01299 | DB01309 | 698 | 1,254 | [
"DDInter1722",
"DDInter933"
] | Sulfadoxine | Insulin glulisine | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
698,
24,
1254
]
],
[
[
698,
1,
1247
],
[
1247,
24,
1254
]
],
[
[
698,
63,
305
],
[
305,
24,
1254
]
],
[
[
698,
24,
850
],
[
850,
... | [
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Sulfadoxine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u... | Sulfadoxine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase E... |
DB01041 | DB06663 | 770 | 1,154 | [
"DDInter1789",
"DDInter1398"
] | Thalidomide | Pasireotide | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
770,
24,
1154
]
],
[
[
770,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
770,
63,
112
],
[
112,
23,
1154
]
],
[
[
770,
63,
88
],
[
88,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Ef... | Thalidomide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when t... |
DB00924 | DB09272 | 1,405 | 412 | [
"DDInter454",
"DDInter632"
] | Cyclobenzaprine | Eluxadoline | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1405,
24,
412
]
],
[
[
1405,
74,
1594
],
[
1594,
24,
412
]
],
[
[
1405,
63,
543
],
[
543,
24,
412
]
],
[
[
1405,
24,
830
],
[
830,
... | [
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases w... | Cyclobenzaprine (Compound) resembles Doxylamine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cyclobenzaprine may cause a moderate intera... |
DB00196 | DB00455 | 600 | 1,601 | [
"DDInter743",
"DDInter1091"
] | Fluconazole | Loratadine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Minor | 0 | [
[
[
600,
23,
1601
]
],
[
[
600,
6,
8374
],
[
8374,
45,
1601
]
],
[
[
600,
21,
29106
],
[
29106,
60,
1601
]
],
[
[
600,
23,
609
],
[
609,
... | [
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Loratadine"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loratadine (Compound)
Fluconazole (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Loratadine (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Cla... |
DB00604 | DB01255 | 1,425 | 633 | [
"DDInter385",
"DDInter1078"
] | Cisapride | Lisdexamfetamine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Major | 2 | [
[
[
1425,
25,
633
]
],
[
[
1425,
23,
112
],
[
112,
23,
633
]
],
[
[
1425,
64,
1494
],
[
1494,
24,
633
]
],
[
[
1425,
24,
286
],
[
286,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lisdexamfetamine
Cisapride may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron ... |
DB00762 | DB01097 | 613 | 1,377 | [
"DDInter973",
"DDInter1033"
] | Irinotecan | Leflunomide | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
613,
25,
1377
]
],
[
[
613,
6,
17404
],
[
17404,
45,
1377
]
],
[
[
613,
7,
9489
],
[
9489,
46,
1377
]
],
[
[
613,
7,
8386
],
[
8386,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Irinotecan",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"Leflunom... | Irinotecan (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Leflunomide (Compound)
Irinotecan (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Leflunomide (Compound)
Irinotecan (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Leflunomide (Compound)
Irinotecan (Com... |
DB00279 | DB01577 | 1,152 | 1,529 | [
"DDInter1074",
"DDInter1161"
] | Liothyronine | Metamfetamine | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Moderate | 1 | [
[
[
1152,
24,
1529
]
],
[
[
1152,
24,
939
],
[
939,
40,
1529
]
],
[
[
1152,
63,
80
],
[
80,
40,
1529
]
],
[
[
1152,
24,
93
],
[
93,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Metamfe... |
DB00475 | DB04868 | 1,119 | 478 | [
"DDInter355",
"DDInter1293"
] | Chlordiazepoxide | Nilotinib | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1119,
24,
478
]
],
[
[
1119,
6,
8374
],
[
8374,
45,
478
]
],
[
[
1119,
23,
126
],
[
126,
24,
478
]
],
[
[
1119,
23,
1384
],
[
1384,
... | [
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Chlordiazepoxide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Chlordiazepoxi... |
DB00818 | DB00983 | 898 | 480 | [
"DDInter1538",
"DDInter776"
] | Propofol | Formoterol | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
898,
24,
480
]
],
[
[
898,
24,
1148
],
[
1148,
63,
480
]
],
[
[
898,
6,
8717
],
[
8717,
45,
480
]
],
[
[
898,
21,
28963
],
[
28963,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Propofol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Propofol (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Formoterol (Compound)
Propofol (Compound... |
DB00562 | DB00682 | 1,014 | 126 | [
"DDInter188",
"DDInter1951"
] | Benzthiazide | Warfarin | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Minor | 0 | [
[
[
1014,
23,
126
]
],
[
[
1014,
24,
135
],
[
135,
62,
126
]
],
[
[
1014,
1,
359
],
[
359,
62,
126
]
],
[
[
1014,
1,
323
],
[
323,
2... | [
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
],
[
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Benzthiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a minor interaction tha... |
DB00816 | DB11978 | 1,674 | 124 | [
"DDInter1346",
"DDInter822"
] | Orciprenaline | Glasdegib | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1674,
24,
124
]
],
[
[
1674,
24,
1079
],
[
1079,
24,
124
]
],
[
[
1674,
24,
1032
],
[
1032,
63,
124
]
],
[
[
1674,
63,
79
],
[
79,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol a... |
DB00618 | DB00653 | 1,572 | 544 | [
"DDInter498",
"DDInter1120"
] | Demeclocycline | Magnesium sulfate | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Moderate | 1 | [
[
[
1572,
24,
544
]
],
[
[
1572,
24,
1473
],
[
1473,
63,
544
]
],
[
[
1572,
1,
1545
],
[
1545,
24,
544
]
],
[
[
1572,
1,
1669
],
[
1669,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gl... | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Demeclocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline ... |
DB00280 | DB00366 | 494 | 1,594 | [
"DDInter575",
"DDInter600"
] | Disopyramide | Doxylamine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
494,
35,
1594
]
],
[
[
494,
25,
11
],
[
11,
1,
1594
]
],
[
[
494,
24,
662
],
[
662,
63,
1594
]
],
[
[
494,
1,
11439
],
[
11439,
... | [
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Disopyramide (Compound) resembles Doxylamine (Compound) and
Disopyramide may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Doxylamine (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Ca... |
DB09123 | DB11767 | 1,525 | 1,583 | [
"DDInter546",
"DDInter1643"
] | Dienogest | Sarilumab | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
1525,
24,
1583
]
],
[
[
1525,
63,
1362
],
[
1362,
24,
1583
]
],
[
[
1525,
63,
1064
],
[
1064,
25,
1583
]
],
[
[
1525,
63,
1362
],
[
13... | [
[
[
"Dienogest",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Dienogest",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"... | Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine ma... |
DB00827 | DB01229 | 646 | 973 | [
"DDInter383",
"DDInter1377"
] | Cinoxacin | Paclitaxel | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Minor | 0 | [
[
[
646,
23,
973
]
],
[
[
646,
21,
29310
],
[
29310,
60,
973
]
],
[
[
646,
25,
1220
],
[
1220,
63,
973
]
],
[
[
646,
62,
134
],
[
134,
... | [
[
[
"Cinoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Cinoxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Toxic epidermal necrolysis"
],
[
"Toxic epidermal necrolysis",
... | Cinoxacin (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Paclitaxel (Compound)
Cinoxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases ... |
DB00262 | DB00501 | 552 | 752 | [
"DDInter302",
"DDInter380"
] | Carmustine | Cimetidine | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Major | 2 | [
[
[
552,
25,
752
]
],
[
[
552,
6,
7950
],
[
7950,
45,
752
]
],
[
[
552,
21,
29062
],
[
29062,
60,
752
]
],
[
[
552,
23,
1467
],
[
1467,
... | [
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
]
],
[
[
"Carmustine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetid... | Carmustine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cimetidine (Compound)
Carmustine (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Cimetidine (Compound)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enox... |
DB00295 | DB00909 | 475 | 306 | [
"DDInter1244",
"DDInter1971"
] | Morphine | Zonisamide | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Moderate | 1 | [
[
[
475,
24,
306
]
],
[
[
475,
6,
8374
],
[
8374,
45,
306
]
],
[
[
475,
21,
28691
],
[
28691,
60,
306
]
],
[
[
475,
24,
1609
],
[
1609,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zonisamide (Compound)
Morphine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Zonisamide (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pento... |
DB00736 | DB14006 | 660 | 972 | [
"DDInter676",
"DDInter370"
] | Esomeprazole | Choline salicylate | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Minor | 0 | [
[
[
660,
23,
972
]
],
[
[
660,
1,
379
],
[
379,
23,
972
]
],
[
[
660,
40,
837
],
[
837,
23,
972
]
],
[
[
660,
25,
1347
],
[
1347,
24... | [
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Choline salicylate"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cau... | Esomeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Choline salicylate
Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken wi... |
DB00795 | DB11256 | 50 | 95 | [
"DDInter1725",
"DDInter1057"
] | Sulfasalazine | Levomefolic acid | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma . It is transported across the membranes including the blood-brain barrier into various tissues where it plays an e... | Minor | 0 | [
[
[
50,
23,
95
]
],
[
[
50,
63,
663
],
[
663,
24,
95
]
],
[
[
50,
62,
1147
],
[
1147,
63,
639
],
[
639,
24,
95
]
],
[
[
50,
63,
... | [
[
[
"Sulfasalazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levomefolic acid"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Levomefolic acid
Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Leucovo... |
DB01211 | DB01238 | 609 | 673 | [
"DDInter393",
"DDInter118"
] | Clarithromycin | Aripiprazole | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
609,
24,
673
]
],
[
[
609,
63,
851
],
[
851,
1,
673
]
],
[
[
609,
63,
827
],
[
827,
40,
673
]
],
[
[
609,
6,
21998
],
[
21998,
4... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (... |
DB01403 | DB01409 | 9 | 1,415 | [
"DDInter1175",
"DDInter1815"
] | Methotrimeprazine | Tiotropium | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
9,
24,
1415
]
],
[
[
9,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
9,
21,
28681
],
[
28681,
60,
1415
]
],
[
[
9,
1,
146
],
[
146,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Methotrimeprazine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} ... | Methotrimeprazine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Methotrimeprazine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Tiotropium (Compound)
Methotrimeprazine (Compound) resembles Propiomazine (Compound) and Propiomazine may ... |
DB00759 | DB01144 | 1,620 | 1,326 | [
"DDInter1783",
"DDInter540"
] | Tetracycline | Diclofenamide | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Minor | 0 | [
[
[
1620,
23,
1326
]
],
[
[
1620,
23,
504
],
[
504,
1,
1326
]
],
[
[
1620,
23,
359
],
[
359,
40,
1326
]
],
[
[
1620,
1,
964
],
[
964,
... | [
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenamide"
]
],
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
... | Tetracycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide and Chlorothiazide (Compound) res... |
DB00087 | DB11834 | 599 | 1,303 | [
"DDInter41",
"DDInter849"
] | Alemtuzumab | Guselkumab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
599,
24,
1303
]
],
[
[
599,
24,
949
],
[
949,
24,
1303
]
],
[
[
599,
24,
287
],
[
287,
63,
1303
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Alemtuzumab... |
DB00679 | DB11130 | 684 | 407 | [
"DDInter1796",
"DDInter1344"
] | Thioridazine | Opium | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
684,
24,
407
]
],
[
[
684,
24,
662
],
[
662,
24,
407
]
],
[
[
684,
36,
104
],
[
104,
24,
407
]
],
[
[
684,
63,
1233
],
[
1233,
2... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Thioridazine (Compound) resembles Methdilazine (Compound) and Thioridazine may lead to a major life threateni... |
DB00550 | DB08827 | 99 | 990 | [
"DDInter1541",
"DDInter1085"
] | Propylthiouracil | Lomitapide | A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
99,
25,
990
]
],
[
[
99,
21,
28658
],
[
28658,
60,
990
]
],
[
[
99,
63,
322
],
[
322,
24,
990
]
],
[
[
99,
24,
126
],
[
126,
24,... | [
[
[
"Propylthiouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Propylthiouracil",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by... | Propylthiouracil (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Lomitapide (Compound)
Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB04845 | DB14443 | 309 | 987 | [
"DDInter1001",
"DDInter1931"
] | Ixabepilone | Vibrio cholerae CVD 103-HgR strain live antigen | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
309,
24,
987
]
],
[
[
309,
24,
1480
],
[
1480,
24,
987
]
],
[
[
309,
63,
1220
],
[
1220,
24,
987
]
],
[
[
309,
64,
581
],
[
581,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ixabepilone may cause a moderate interaction that could exacerbate diseases wh... |
DB08816 | DB12825 | 578 | 1,375 | [
"DDInter1802",
"DDInter1032"
] | Ticagrelor | Lefamulin | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
578,
24,
1375
]
],
[
[
578,
24,
159
],
[
159,
63,
1375
]
],
[
[
578,
63,
1101
],
[
1101,
24,
1375
]
],
[
[
578,
24,
98
],
[
98,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and B... |
DB00601 | DB00641 | 453 | 467 | [
"DDInter1073",
"DDInter1675"
] | Linezolid | Simvastatin | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Moderate | 1 | [
[
[
453,
24,
467
]
],
[
[
453,
7,
3163
],
[
3163,
46,
467
]
],
[
[
453,
18,
2023
],
[
2023,
46,
467
]
],
[
[
453,
7,
10578
],
[
10578,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Linezolid",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
"TSC22D3",
"{u} (Gene) is upregulated by {v}... | Linezolid (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Simvastatin (Compound)
Linezolid (Compound) downregulates RAP1GAP (Gene) and RAP1GAP (Gene) is upregulated by Simvastatin (Compound)
Linezolid (Compound) upregulates PRKAG2 (Gene) and PRKAG2 (Gene) is downregulated by Simvastatin (Comp... |
DB00332 | DB00557 | 1,089 | 252 | [
"DDInter970",
"DDInter895"
] | Ipratropium | Hydroxyzine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Moderate | 1 | [
[
[
1089,
24,
252
]
],
[
[
1089,
24,
1630
],
[
1630,
1,
252
]
],
[
[
1089,
24,
623
],
[
623,
40,
252
]
],
[
[
1089,
24,
537
],
[
537,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Hydroxyzine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Co... |
DB00358 | DB00818 | 1,010 | 898 | [
"DDInter1140",
"DDInter1538"
] | Mefloquine | Propofol | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Moderate | 1 | [
[
[
1010,
24,
898
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
898
]
],
[
[
1010,
21,
28785
],
[
28785,
60,
898
]
],
[
[
1010,
23,
112
],
[
112... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Propofol (Compound)
Mefloquine (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Propofol (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and... |
DB00865 | DB01261 | 939 | 170 | [
"DDInter187",
"DDInter1679"
] | Benzphetamine | Sitagliptin | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
939,
24,
170
]
],
[
[
939,
6,
8374
],
[
8374,
45,
170
]
],
[
[
939,
21,
28921
],
[
28921,
60,
170
]
],
[
[
939,
24,
52
],
[
52,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Benzphetamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Benzphetamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Benzphetamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dulaglut... |
DB06186 | DB08870 | 1,439 | 850 | [
"DDInter969",
"DDInter228"
] | Ipilimumab | Brentuximab vedotin | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1439,
24,
850
]
],
[
[
1439,
24,
788
],
[
788,
24,
850
]
],
[
[
1439,
63,
671
],
[
671,
24,
850
]
],
[
[
1439,
24,
1468
],
[
1468,
... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvasta... |
DB00980 | DB09054 | 969 | 384 | [
"DDInter1564",
"DDInter905"
] | Ramelteon | Idelalisib | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
969,
24,
384
]
],
[
[
969,
24,
222
],
[
222,
23,
384
]
],
[
[
969,
63,
600
],
[
600,
24,
384
]
],
[
[
969,
24,
868
],
[
868,
24,... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flucona... |
DB08881 | DB09268 | 868 | 1,662 | [
"DDInter1925",
"DDInter1464"
] | Vemurafenib | Picosulfuric acid | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
868,
24,
1662
]
],
[
[
868,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
868,
64,
1164
],
[
1164,
24,
1662
]
],
[
[
868,
25,
484
],
[
484,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Vemurafenib may lead to a major life threatening interaction when taken with Trimipramine and Trimipramine may c... |
DB01232 | DB12941 | 1,327 | 466 | [
"DDInter1640",
"DDInter481"
] | Saquinavir | Darolutamide | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
1327,
24,
466
]
],
[
[
1327,
25,
1374
],
[
1374,
23,
466
]
],
[
[
1327,
64,
600
],
[
600,
23,
466
]
],
[
[
1327,
63,
86
],
[
86,
... | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abirate... | Saquinavir may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Saquinavir may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor int... |
DB01060 | DB01211 | 319 | 609 | [
"DDInter83",
"DDInter393"
] | Amoxicillin | Clarithromycin | Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin. Amoxicillin was granted FDA approval on 18 January 1974. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Minor | 0 | [
[
[
319,
23,
609
]
],
[
[
319,
62,
1570
],
[
1570,
24,
609
]
],
[
[
319,
6,
10215
],
[
10215,
45,
609
]
],
[
[
319,
18,
2114
],
[
2114,
... | [
[
[
"Amoxicillin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Amoxicillin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Azithromycin"
],
... | Amoxicillin may cause a minor interaction that can limit clinical effects when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Amoxicillin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound)
Amox... |
DB01128 | DB04835 | 918 | 1,655 | [
"DDInter204",
"DDInter1125"
] | Bicalutamide | Maraviroc | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
918,
24,
1655
]
],
[
[
918,
6,
8374
],
[
8374,
45,
1655
]
],
[
[
918,
21,
28792
],
[
28792,
60,
1655
]
],
[
[
918,
63,
888
],
[
888,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Bicalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Bicalutamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Maraviroc (Compound)
Bicalutamide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Maraviroc (Compound)
Bicalutamide may cause a moderate interaction that could exacerbate diseases... |
DB01001 | DB09082 | 688 | 659 | [
"DDInter1632",
"DDInter1934"
] | Salbutamol | Vilanterol | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
688,
24,
659
]
],
[
[
688,
23,
1220
],
[
1220,
23,
659
]
],
[
[
688,
62,
891
],
[
891,
23,
659
]
],
[
[
688,
63,
1570
],
[
1570,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Pred... |
DB00443 | DB01261 | 251 | 170 | [
"DDInter195",
"DDInter1679"
] | Betamethasone | Sitagliptin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
251,
24,
170
]
],
[
[
251,
6,
8374
],
[
8374,
45,
170
]
],
[
[
251,
7,
5774
],
[
5774,
46,
170
]
],
[
[
251,
7,
6448
],
[
6448,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Betamethasone (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Sitagliptin (Compound)
Betamethasone (Compound) upregulates CTSD (Gene) and CTSD (Gene) is downregulated by Sitagliptin (Compound)
Betameth... |
DB00564 | DB06335 | 1,236 | 761 | [
"DDInter293",
"DDInter1646"
] | Carbamazepine | Saxagliptin | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1236,
24,
761
]
],
[
[
1236,
6,
7524
],
[
7524,
45,
761
]
],
[
[
1236,
21,
29226
],
[
29226,
60,
761
]
],
[
[
1236,
40,
307
],
[
307,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Comp... | Carbamazepine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Saxagliptin (Compound)
Carbamazepine (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Saxagliptin (Compound)
Carbamazepine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction th... |
DB01036 | DB01114 | 211 | 272 | [
"DDInter1832",
"DDInter362"
] | Tolterodine | Chlorpheniramine | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
211,
35,
272
]
],
[
[
211,
1,
358
],
[
358,
63,
272
]
],
[
[
211,
40,
11244
],
[
11244,
1,
272
]
],
[
[
211,
1,
11296
],
[
11296,
... | [
[
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
... | Tolterodine (Compound) resembles Chlorpheniramine (Compound) and
Tolterodine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Tolterodine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) r... |
DB00046 | DB01611 | 1,179 | 1,487 | [
"DDInter940",
"DDInter893"
] | Insulin lispro | Hydroxychloroquine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1179,
24,
1487
]
],
[
[
1179,
24,
1247
],
[
1247,
23,
1487
]
],
[
[
1179,
24,
168
],
[
168,
24,
1487
]
],
[
[
1179,
63,
521
],
[
521,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethox... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken ... |
DB01174 | DB09112 | 697 | 1,455 | [
"DDInter1442",
"DDInter1306"
] | Phenobarbital | Nitrous acid | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Major | 2 | [
[
[
697,
25,
1455
]
],
[
[
697,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
697,
63,
1214
],
[
1214,
24,
1455
]
],
[
[
697,
24,
1311
],
[
1311,
... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Minoxid... |
DB00443 | DB04861 | 251 | 1,592 | [
"DDInter195",
"DDInter1271"
] | Betamethasone | Nebivolol | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
251,
24,
1592
]
],
[
[
251,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
251,
23,
1283
],
[
1283,
23,
1592
]
],
[
[
251,
24,
1479
],
[
1479... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is c... | Betamethasone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken wit... |
DB00912 | DB00951 | 473 | 1,072 | [
"DDInter1581",
"DDInter986"
] | Repaglinide | Isoniazid | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
473,
24,
1072
]
],
[
[
473,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
473,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
473,
24,
1486
],
[
1486,... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Repaglinide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and M... |
DB04868 | DB08931 | 478 | 947 | [
"DDInter1293",
"DDInter1600"
] | Nilotinib | Riociguat | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
478,
24,
947
]
],
[
[
478,
63,
379
],
[
379,
24,
947
]
],
[
[
478,
24,
1478
],
[
1478,
24,
947
]
],
[
[
478,
64,
609
],
[
609,
2... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacafto... |
DB01069 | DB13913 | 401 | 1,536 | [
"DDInter1533",
"DDInter175"
] | Promethazine | Belladonna | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as ... | Moderate | 1 | [
[
[
401,
24,
1536
]
],
[
[
401,
24,
849
],
[
849,
24,
1536
]
],
[
[
401,
63,
128
],
[
128,
24,
1536
]
],
[
[
401,
64,
1425
],
[
1425,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramin... |
DB00026 | DB14962 | 1,184 | 1,363 | [
"DDInter94",
"DDInter1847"
] | Anakinra | Trastuzumab deruxtecan | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Moderate | 1 | [
[
[
1184,
24,
1363
]
],
[
[
1184,
24,
1430
],
[
1430,
24,
1363
]
],
[
[
1184,
25,
1259
],
[
1259,
25,
1363
]
],
[
[
1184,
64,
1057
],
[
10... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Anakinra may lead to a major life threatening interaction when taken with Baricitinib and Bariciti... |
DB04948 | DB11986 | 1,084 | 484 | [
"DDInter1083",
"DDInter648"
] | Lofexidine | Entrectinib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1084,
24,
484
]
],
[
[
1084,
62,
112
],
[
112,
23,
484
]
],
[
[
1084,
63,
222
],
[
222,
23,
484
]
],
[
[
1084,
24,
774
],
[
774,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Si... |
DB01224 | DB09074 | 623 | 1,362 | [
"DDInter1553",
"DDInter1327"
] | Quetiapine | Olaparib | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
623,
24,
1362
]
],
[
[
623,
63,
353
],
[
353,
24,
1362
]
],
[
[
623,
24,
1619
],
[
1619,
63,
1362
]
],
[
[
623,
64,
1425
],
[
1425,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucap... |
DB00569 | DB15233 | 553 | 1,650 | [
"DDInter775",
"DDInter142"
] | Fondaparinux | Avapritinib | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
553,
25,
1650
]
],
[
[
553,
24,
557
],
[
557,
24,
1650
]
],
[
[
553,
25,
1512
],
[
1512,
25,
1650
]
],
[
[
553,
64,
1578
],
[
1578,
... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
... | Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Fondaparinux may lead to a major life threatening interaction when taken with Diclofenac and Dicl... |
DB00434 | DB00472 | 13 | 758 | [
"DDInter459",
"DDInter758"
] | Cyproheptadine | Fluoxetine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
13,
24,
758
]
],
[
[
13,
24,
358
],
[
358,
1,
758
]
],
[
[
13,
24,
109
],
[
109,
40,
758
]
],
[
[
13,
6,
7390
],
[
7390,
45,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Fluoxetine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) resembles Fluoxetine... |
DB00390 | DB12015 | 1,252 | 1,033 | [
"DDInter554",
"DDInter53"
] | Digoxin | Alpelisib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1252,
24,
1033
]
],
[
[
1252,
24,
1344
],
[
1344,
24,
1033
]
],
[
[
1252,
63,
837
],
[
837,
24,
1033
]
],
[
[
1252,
23,
170
],
[
170,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Panto... |
DB08875 | DB14881 | 1,618 | 180 | [
"DDInter262",
"DDInter1329"
] | Cabozantinib | Oliceridine | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
1618,
25,
180
]
],
[
[
1618,
62,
112
],
[
112,
23,
180
]
],
[
[
1618,
64,
401
],
[
401,
24,
180
]
],
[
[
1618,
24,
1094
],
[
1094,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Cabozantinib may lead to a major life threatening interaction when taken with Promethazine and Promethazine... |
DB00218 | DB01218 | 1,176 | 1,493 | [
"DDInter1247",
"DDInter852"
] | Moxifloxacin | Halofantrine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
1176,
25,
1493
]
],
[
[
1176,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
1176,
23,
112
],
[
112,
23,
1493
]
],
[
[
1176,
24,
770
],
[
770... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side ... | Moxifloxacin (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical... |
DB00372 | DB14881 | 999 | 180 | [
"DDInter1793",
"DDInter1329"
] | Thiethylperazine | Oliceridine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
999,
24,
180
]
],
[
[
999,
24,
401
],
[
401,
24,
180
]
],
[
[
999,
63,
1648
],
[
1648,
24,
180
]
],
[
[
999,
23,
286
],
[
286,
2... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Alde... |
DB00884 | DB06723 | 1,008 | 115 | [
"DDInter1604",
"DDInter58"
] | Risedronic acid | Aluminum hydroxide | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1008,
24,
115
]
],
[
[
1008,
21,
28643
],
[
28643,
60,
115
]
],
[
[
1008,
40,
1199
],
[
1199,
24,
115
]
],
[
[
1008,
24,
428
],
[
428,... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Risedronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Si... | Risedronic acid (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Risedronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Risedronic acid ... |
DB00497 | DB06168 | 828 | 1,531 | [
"DDInter1366",
"DDInter281"
] | Oxycodone | Canakinumab | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
828,
24,
1531
]
],
[
[
828,
24,
1476
],
[
1476,
63,
1531
]
],
[
[
828,
24,
1213
],
[
1213,
24,
1531
]
],
[
[
828,
25,
1419
],
[
1419,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatini... |
DB04844 | DB09020 | 843 | 28 | [
"DDInter1778",
"DDInter212"
] | Tetrabenazine | Bisacodyl | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
843,
24,
28
]
],
[
[
843,
63,
662
],
[
662,
1,
28
]
],
[
[
843,
63,
128
],
[
128,
40,
28
]
],
[
[
843,
6,
4495
],
[
4495,
57,
... | [
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Bisacodyl (Compound)
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine (Compound) resem... |
DB00582 | DB11718 | 1,622 | 927 | [
"DDInter1946",
"DDInter640"
] | Voriconazole | Encorafenib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1622,
25,
927
]
],
[
[
1622,
23,
112
],
[
112,
23,
927
]
],
[
[
1622,
24,
720
],
[
720,
24,
927
]
],
[
[
1622,
63,
1324
],
[
1324,
... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Voriconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Voriconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil an... |
DB00439 | DB00773 | 289 | 896 | [
"DDInter341",
"DDInter702"
] | Cerivastatin | Etoposide | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
289,
24,
896
]
],
[
[
289,
24,
147
],
[
147,
23,
896
]
],
[
[
289,
24,
310
],
[
310,
63,
896
]
],
[
[
289,
24,
322
],
[
322,
24,... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Ca... |
DB00349 | DB00651 | 902 | 746 | [
"DDInter401",
"DDInter613"
] | Clobazam | Dyphylline | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Minor | 0 | [
[
[
902,
23,
746
]
],
[
[
902,
62,
1031
],
[
1031,
1,
746
]
],
[
[
902,
21,
28762
],
[
28762,
60,
746
]
],
[
[
902,
40,
1418
],
[
1418,
... | [
[
[
"Clobazam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dyphylline"
]
],
[
[
"Clobazam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"T... | Clobazam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline (Compound) resembles Dyphylline (Compound)
Clobazam (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Dyphylline (Compound)
Clobazam (Compound) resembles Estazolam (Compoun... |
DB00985 | DB01069 | 1,443 | 401 | [
"DDInter562",
"DDInter1533"
] | Dimenhydrinate | Promethazine | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1443,
24,
401
]
],
[
[
1443,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1443,
63,
104
],
[
104,
24,
401
]
],
[
[
1443,
6,
4304
],
[
4304,
... | [
[
[
"Dimenhydrinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Dimenhydrinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and ... |
DB00363 | DB00515 | 695 | 589 | [
"DDInter419",
"DDInter387"
] | Clozapine | Cisplatin | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Major | 2 | [
[
[
695,
25,
589
]
],
[
[
695,
6,
6017
],
[
6017,
45,
589
]
],
[
[
695,
25,
1468
],
[
1468,
63,
589
]
],
[
[
695,
64,
367
],
[
367,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Cisplatin"... | Clozapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Cisplatin (Compound)
Clozapine may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Clozapine may lead to a major life thre... |
DB00467 | DB01132 | 1,467 | 1,130 | [
"DDInter644",
"DDInter1472"
] | Enoxacin | Pioglitazone | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1467,
24,
1130
]
],
[
[
1467,
40,
739
],
[
739,
24,
1130
]
],
[
[
1467,
25,
870
],
[
870,
24,
1130
]
],
[
[
1467,
64,
1179
],
[
1179,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moder... | Enoxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Enoxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could ex... |
DB00722 | DB01309 | 743 | 1,254 | [
"DDInter1079",
"DDInter933"
] | Lisinopril | Insulin glulisine | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
743,
24,
1254
]
],
[
[
743,
25,
1621
],
[
1621,
23,
1254
]
],
[
[
743,
25,
948
],
[
948,
62,
1254
]
],
[
[
743,
24,
167
],
[
167,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Lisinopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
... | Lisinopril may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Lisinopril may lead to a major life threatening interaction when taken with Potassium gluconate and Potass... |
DB06403 | DB08899 | 1,204 | 129 | [
"DDInter62",
"DDInter649"
] | Ambrisentan | Enzalutamide | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the Un... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1204,
24,
129
]
],
[
[
1204,
25,
1510
],
[
1510,
24,
129
]
],
[
[
1204,
63,
79
],
[
79,
24,
129
]
],
[
[
1204,
24,
1320
],
[
1320,
... | [
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ambrisentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Ter... | Ambrisentan may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib ma... |
DB00209 | DB01004 | 352 | 563 | [
"DDInter1886",
"DDInter806"
] | Trospium | Ganciclovir | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
352,
24,
563
]
],
[
[
352,
24,
1295
],
[
1295,
1,
563
]
],
[
[
352,
24,
248
],
[
248,
40,
563
]
],
[
[
352,
21,
29095
],
[
29095,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir and Valaciclovir (Compound) resembles Ganciclovir (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (... |
DB01309 | DB14731 | 1,254 | 1,518 | [
"DDInter933",
"DDInter1741"
] | Insulin glulisine | Tagraxofusp | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
1254,
24,
1518
]
],
[
[
1254,
63,
123
],
[
123,
24,
1518
]
],
[
[
1254,
24,
5
],
[
5,
24,
1518
]
],
[
[
1254,
63,
695
],
[
695,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Liraglut... |
DB06372 | DB12240 | 259 | 110 | [
"DDInter1594",
"DDInter1485"
] | Rilonacept | Polatuzumab vedotin | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
259,
24,
110
]
],
[
[
259,
63,
467
],
[
467,
24,
110
]
],
[
[
259,
64,
980
],
[
980,
24,
110
]
],
[
[
259,
24,
951
],
[
951,
24,... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Rilonacept may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizum... |
DB01018 | DB09054 | 1,364 | 384 | [
"DDInter847",
"DDInter905"
] | Guanfacine | Idelalisib | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
1364,
25,
384
]
],
[
[
1364,
63,
891
],
[
891,
24,
384
]
],
[
[
1364,
40,
1512
],
[
1512,
24,
384
]
],
[
[
1364,
64,
600
],
[
600,
... | [
[
[
"Guanfacine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Predniso... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Guanfacine (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a moderate interaction that c... |
DB00026 | DB01281 | 1,184 | 881 | [
"DDInter94",
"DDInter5"
] | Anakinra | Abatacept | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Moderate | 1 | [
[
[
1184,
24,
881
]
],
[
[
1184,
23,
1193
],
[
1193,
62,
881
]
],
[
[
1184,
23,
1461
],
[
1461,
23,
881
]
],
[
[
1184,
24,
4
],
[
4,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abatacept"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Abatacept
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.